Dr. Greenbaum works with the Experimental Medicine Unit (EMU) at BRI to understand the biology behind experimental therapies. Most of these studies focus on type 1 diabetes (T1D). Some of the research projects our group has investigated in collaboration with the EMU include:
- Siltuximab and Tocilizumab in T1D
- AIRmax as a measure of functional beta cell mass in at-risk individuals for T1D
- Defining early markers of response to Abatacept in new onset T1D
- Kinetics of immune cell turnover
- Longitudinal evaluation of immune biomarkers in T1D, T2D
